CLINICAL EVALUATION OF IFN BETA1B IN COVID-19 PNEUMONIA: A
RETROSPECTIVE STUDY

https://doi.org/10.1101/2020.05.15.20084293

In this retrospective cohort study, 256 patients (106 patients in interferon group and 150 patients in control group) were analyzed. In the interferon group, more patients received hydroxychloroquine (95.3% vs. 64%, p<0.001) and lopinavir/ritonavir (44.3% vs. 30.2%, p=0.021). There was no difference in in-hospital mortality between the group receiving the combination of interferon beta1b and lopinavir/ritonavir versus the group of patients receiving interferon beta1b without lopinavir/ritonavir (p=0.906). The overall mortality rate was 24.6% (63/256). Twenty-two patients (20.8%) receiving interferon beta1b died and 41 (27.3%) patients not receiving interferon beta1b. The interferon beta1b treatment had no significant impact on in-hospital survival. Authors consider that it would be of interest to explore the efficacy of the early administration of this drug in controlled clinical trials, with a larger sample size.

Tags: